drugset / Trial / NCT07248280

Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

NCT07248280

Phase 3 Recruiting 260 enrolled University of Montreal Hospital Centre (CHUM)
RandomizedParallel-groupTriple-blindPrevention

Summary

Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.

Timeline

Start
2026-02-27
Primary completion
2026-07-01
Completion
2027-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 40 mg Oral

Indications

No indication recorded.